-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Drug-Related Side Effects and Adverse Reactions are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Drug-Related Side Effects and Adverse Reactions.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- Elucidating mechanisms of drug-induced toxicity.
Liebler DC, Guengerich FP
(2005) Nat Rev Drug Discov 4: 410-20 - Prenatal exposure to drugs: effects on brain development and implications for policy and education.
Thompson BL, Levitt P, Stanwood GD
(2009) Nat Rev Neurosci 10: 303-12 - Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing.
Kessler C, Ward MJ, McNaughton CD
(2016) JAMA 316: 2092-2093 - Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
(2013) Lancet Oncol 14: 371-82 - Computational methods in drug discovery.
Sliwoski G, Kothiwale S, Meiler J, Lowe EW
(2014) Pharmacol Rev 66: 334-95 - Drug-induced long QT syndrome.
Kannankeril P, Roden DM, Darbar D
(2010) Pharmacol Rev 62: 760-81 - Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A
(2009) J Clin Oncol 27: 1075-81 - Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine?
Roden DM, Hong CC
(2013) Circulation 127: 1641-3 - The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes.
Behr ER, January C, Schulze-Bahr E, Grace AA, Kääb S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M, Roden D
(2013) Eur Heart J 34: 1958-63 - Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, Van Driest S, Karnes JH, Ingram C, Guo Y, Shyr Y, Norris K, Kannankeril PJ, Ramirez AH, Smith JD, Mardis ER, Nickerson D, George AL, Roden DM
(2014) J Am Coll Cardiol 63: 1430-7 - Guidelines for drug therapy in renal failure.
Bennett WM, Singer I, Golper T, Feig P, Coggins CJ
(1977) Ann Intern Med 86: 754-83 - The incidence and severity of adverse events affecting patients after discharge from the hospital.
Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW
(2003) Ann Intern Med 138: 161-7 - Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci.
Gamazon ER, Huang RS, Cox NJ, Dolan ME
(2010) Proc Natl Acad Sci U S A 107: 9287-92 - Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME, Tuberculosis Trials Consortium
(2015) Clin Infect Dis 61: 527-35 - A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA
(2017) Clin Cancer Res 23: 4035-4045 - Clinical studies of drug effects in humans.
Ray WA
(1996) Clin Chem 42: 1306-11 - Postmarketing surveillance for drug safety: surely we can do better.
Griffin MR, Stein CM, Ray WA
(2004) Clin Pharmacol Ther 75: 491-4 - Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.
Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, Cowan JD, Xu H, Ramirez AH, Crawford DC, Ritchie MD, Peterson JF, Masys DR, Wilke RA, Roden DM
(2012) Clin Pharmacol Ther 92: 235-42 - The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ
(2012) Clin Pharmacol Ther 92: 446-9 - Pharmacogenomics at the tipping point: challenges and opportunities.
Roden DM, Tyndale RF
(2011) Clin Pharmacol Ther 89: 323-7 - Response to "Doubt about the feasibility of preemptive genotyping".
Denny JC, Schildcrout JS, Pulley JM, Roden DM
(2013) Clin Pharmacol Ther 93: 234 - The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D
(2011) Clin Pharmacol Ther 89: 784-5 - Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P
(2013) J Infect Dis 207: 749-58 - Safety of zoster vaccine in elderly adults following documented herpes zoster.
Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW, Shingles Prevention Study Group
(2013) J Infect Dis 208: 559-63 - Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits.
Maranville JC, Cox NJ
(2016) Pharmacogenomics J 16: 388-92 - Attitudes of clinicians following large-scale pharmacogenomics implementation.
Peterson JF, Field JR, Shi Y, Schildcrout JS, Denny JC, McGregor TL, Van Driest SL, Pulley JM, Lubin IM, Laposata M, Roden DM, Clayton EW
(2016) Pharmacogenomics J 16: 393-8 - Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.
Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, Nickerson DA, George AL, Roden DM
(2013) Pharmacogenomics J 13: 325-9 - Computational models of antiviral toxicity.
Samuels DC
(2007) Curr Opin Drug Discov Devel 10: 43-8 - Automated dose-rounding recommendations for pediatric medications.
Johnson KB, Lee CK, Spooner SA, Davison CL, Helmke JS, Weinberg ST
(2011) Pediatrics 128: e422-8 - Adverse drug events during AKI and its recovery.
Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, Lewis J, Danciu I, Bian A, Shintani A, Ikizler TA, Neal EB, Peterson JF
(2013) Clin J Am Soc Nephrol 8: 1070-8 - Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).
Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori SG, Tan HL, Hiraoka M, Brugada J, Wilde AA
(2009) Heart Rhythm 6: 1335-41 - Adverse drug reactions and the elderly.
Ray WA, Griffin MR, Shorr RI
(1990) Health Aff (Millwood) 9: 114-22 - Cytochrome P450s and other enzymes in drug metabolism and toxicity.
Guengerich FP
(2006) AAPS J 8: E101-11 - In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.
Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F
(2018) J Chem Inf Model 58: 943-956 - Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.
Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ, STRAW + 10 Collaborative Group
(2012) Fertil Steril 97: 843-51 - In reply.
Lenihan DJ, Kowey PR
(2014) Oncologist 19: 307 - Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
Lenihan DJ, Kowey PR
(2013) Oncologist 18: 900-8 - Cytochrome p450 and chemical toxicology.
Guengerich FP
(2008) Chem Res Toxicol 21: 70-83 - Applying mechanisms of chemical toxicity to predict drug safety.
Guengerich FP, MacDonald JS
(2007) Chem Res Toxicol 20: 344-69 - Effects of heredity on response to drugs and environmental chemicals: construction of rodent models.
Levy GN, Rodgers L, Weber WW
(1996) Chem Res Toxicol 9: 1215-24
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
